The global anatomic pathology market is projected to grow at a CAGR of nearly 8% during the forecast period. Market expansion is primarily driven by the growing incidence of cancer and chronic ...

The round was led by FCA Venture Partners, with the Labcorp Venture Fund and Epsilon anchoring the final close as the primary investors. Strong participation also came from existing investors, ...

Labcorp’s third quarter results met Wall Street’s revenue expectations, but the market responded negatively, reflecting ...

KCAS Bio, a leading contract research organization (CRO) specializing in comprehensive bioanalytical and biomarker services, is delighted to announce the appointment of Dr. Paul Kirchgraber and Mr.

The company's presence highlights Dublin’s growing reputation as a destination for innovation, connectivity and business ...

Medicare Part B data show that of the 20 CPT codes seeing the largest increase in payments from 2022 to 2024, all are for molecular- or sequencing-based tests.

Labcorp forecast lower annual revenue growth for its contract research unit on Tuesday, as a prolonged funding crunch continues to weigh on its early-stage drug development clients.

Q3 2025 Earnings Call Transcript October 28, 2025 Labcorp Holdings Inc. beats earnings expectations. Reported EPS is $4.18, ...

Healthcare diagnostics company Labcorp Holdings (NYSE:LH) in Q3 CY2025, with sales up 8.6% year on year to $3.56 billion. Its ...

Labcorp posts Q3 EPS of $4.18 and sales of $3.56 billion, exceeding estimates, while revising 2025 guidance amid strong ...

As a leading independent diagnostic laboratory, Labcorp participates in a highly attractive duopoly that offers favorable prospects as healthcare moves toward reformed payment models, Medicare ...